Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2026-06-03

Clinical Trial Results: A Study of Tiragolumab in Combination With Atezolizumab Plus Pemetrexed and Carboplatin/Cisplatin Versus Pembrolizumab Plus Pemetrexed and Carboplatin/Cisplatin in Participants With Previously Untreated Advanced Non-Squamous Non-Small Cell Lung Cancer [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/3 trial evaluating tiragolumab with atezolizumab plus pemetrexed and platinum vs pembrolizumab plus pemetrexed and platinum in untreated advanced non-sq…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Atezolizumab (atezolizumab)
  • CARBOPLATIN (Carboplatin)
  • CISPLATIN (cisplatin)
  • Pembrolizumab (pembrolizumab)
  • Pemetrexed (pemetrexed)
  • Tiragolumab (tiragolumab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Non-small Cell Lung Cancer (NSCLC) | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2026-06-03